Philippe Carteron De Balmont

Biography

 Philippe founded CarthaGenetics in 2004 with the vision that an international expert team could leverage better synergies between biotech companies, physicians and local authorities in order to speed drug development and get more patients treated in Europe. Prior to this, Philippe worked for over two decades as country manager at key biotechnology companies involved in the Orphan Drug (OD) market. Philippe was instrumental in “pre-launching” and “launching” some of the most visible OD brands in EMEA, among them: Ceredase®, Cerezyme®, Replagal®, Naglazyme®, Soliris®, Vyndaqel®, Glybera®, Juxtapid®/Lojuxta™, Gattex®/Revestive®, Metopitone®, Translarna™. As General Manager, Philippe has a passion for medical affairs and key negotiations with government bodies, including Health and Social ministers, regulatory agencies and patient associations, and has been participating in policy development and OD implementation, notably in Turkey. Philippe has a Master in Biology, in Pharmaceutical Marketing (Institut Supérieur de Gestion, Paris 16e), and holds an Executive Master in International Negotiation and Policy Making (The Graduate Institute, IHEID, Geneva). Philippe is based in Geneva, Switzerland.

Research Interest

 Management